See how our MESF & QSC kits support quantitative flow cytometry in cancer research & immunotherapy development Part II

Original posting (Part I): October 12, 2017

Cancer research and immunotherapy development is an ongoing mission. Our Quantum MESF and Quantum Simply Cellular kits continue to support quantitative flow cytometry in cancer research and immunotherapy development. We have updated our curated reference listing to include some more contemporary investigations into cancer diagnostics, characteristics, and potential improvements on advanced therapies.

Bezverbnaya, K., Moogk, D., Cummings, D., Baker, C. L., Aarts, C., Denisova, G., Sun, M., McNicol, J. D., Turner, R. C., Rullo, A. F., Foley, S. R., & Bramson, J. L. (2021). Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. Cytotherapy, 23(9), 820-832.

Dao, T. N., Utturkar, S., Atallah Lanman, N., & Matosevic, S. (2020). TIM-3 expression is Downregulated on human NK cells in response to cancer targets in synergy with activation. Cancers, 12(9), 2417.

Franco Nitta, C., Green, E. W., Jhamba, E. D., Keth, J. M., Ortiz-Caraveo, I., Grattan, R. M., Schodt, D. J., Gibson, A. C., Rajput, A., Lidke, K. A., Wilson, B. S., Steinkamp, M. P., & Lidke, D. S. (2021). Author response: EGFR transactivates RON to drive oncogenic crosstalk.

Gudipati, V., Rydzek, J., Doel-Perez, I., Gonçalves, V. D., Scharf, L., Königsberger, S., Lobner, E., Kunert, R., Einsele, H., Stockinger, H., Hudecek, M., & Huppa, J. B. (2020). Inefficient CAR-proximal signaling blunts antigen sensitivity. Nature Immunology, 21(8), 848-856.

House, B. J., Kwon, M. J., Schaefer, J. M., Barth, C. W., Solanki, A., Davis, S. C., & Gibbs, S. L. (2021). Clinically relevant dual probe difference specimen imaging (DDSI) protocol for freshly resected breast cancer specimen staining. BMC Cancer, 21(1).

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y. T., Rivera, J. M., Marcoulis, M., White, K. L., Whitman, J. D., Bapat, S. P., Parker, K. R., Ramirez, J., Deucher, A., Phojanokong, P., Steri, V., Fattahi, F., Hann, B. C., Satpathy, A. T., Manglik, A., … Wiita, A. P. (2021). Surface Proteomics reveals CD72 as a target for In vitro–evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL. Cancer Discovery, 11(8), 2032-2049.

Rubtsova, N. I., Hart, M. C., Arroyo, A. D., Osharovich, S. A., Liebov, B. K., Miller, J., Yuan, M., Cochran, J. M., Chong, S., Yodh, A. G., Busch, T. M., Delikatny, E. J., Anikeeva, N., & Popov, A. V. (2021). NIR fluorescent imaging and Photodynamic therapy with a novel Theranostic phospholipid probe for triple-negative breast cancer cells. Bioconjugate Chemistry, 32(8), 1852-1863.

Sharma, S., Li, Z., Bussing, D., & Shah, D. K. (2020). Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells. Drug Metabolism and Disposition, 48(5), 368-377.

Su, Y., Zhang, X., Bidlingmaier, S., Behrens, C. R., Lee, N., & Liu, B. (2020). ALPPL2 is a highly specific and targetable tumor cell surface antigen. Cancer Research, 80(20), 4552-4564.

Takehara, T., Wakamatsu, E., Machiyama, H., Nishi, W., Emoto, K., Azuma, M., Soejima, K., Fukunaga, K., & Yokosuka, T. (2021). PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment. Communications Biology, 4(1).